Levi & Korsinsky, LLP Announces Securities Fraud Lawsuit Against Regeneron Pharmaceuticals, Inc.
Levi & Korsinsky, LLP has issued a notice to investors in Regeneron Pharmaceuticals the regarding a class action lawsuit filed against the Company. This lawsuit aims to recover losses incurred by shareholders who were adversely affected by alleged securities fraud between November 2, 2023, and October 30, 2024.
Class Action Details: Seeking Justice for Shareholders
The class action lawsuit alleges that Regeneron engaged in deceptive financial practices that misled investors and artificially inflated stock prices. Specifically, the complaint contends that the Company failed to disclose crucial information regarding its pricing strategies, credit card fee payments, and compliance with federal regulations.
Allegations Against Regeneron
The lawsuit asserts that Regeneron misrepresented or failed to disclose the following:
- Improper Credit Card Fee Payments – Regeneron allegedly paid credit card fees to distributors under the condition that these distributors would not pass the costs onto customers purchasing one of Regeneron’s primary products, Eylea.
- Subsidizing Prices – These payments allegedly subsidized the price customers paid when using credit cards to purchase Eylea, giving an impression of a lower cost than was actually the case.
- Price Concessions and Competitive Advantage – By engaging in this practice, Regeneron effectively provided price concessions that reduced Eylea’s selling price, making it more attractive to retina practices that were sensitive to cost changes when using credit cards.
- Inflated Eylea Sales Reports – Regeneron reportedly misrepresented the sales figures for Eylea by failing to disclose these price concessions, misleading investors about the true performance and financial health of the Company.
- False Claims Act Violations – By not reporting its payment of credit card fees as price concessions, Regeneron allegedly overstated the Average Sales Price (ASP) reported to federal agencies, violating the False Claims Act.
- Misleading Investor Communications – As a result of these practices, the lawsuit claims that Regeneron’s public statements regarding its business, operations, and future prospects were materially misleading and lacked a reasonable basis.
Investors’ Rights and Next Steps
If you purchased Regeneron stock during the specified period and suffered financial losses, you may be eligible to participate in the class action lawsuit. Investors have until March 10, 2025, to request the court to appoint them as lead plaintiffs. Being a lead plaintiff is not required to recover potential damages, but it provides an opportunity to take a more active role in the litigation process.
No Cost or Obligation for Class Members
Participation in this class action lawsuit does not require any upfront payment or out-of-pocket costs. If the lawsuit is successful, affected shareholders may be entitled to compensation without incurring legal fees or expenses.
Why Choose Levi & Korsinsky?
For over two decades, Levi & Korsinsky has been a leader in securities litigation, securing hundreds of millions of dollars in settlements for investors. The firm is recognized as one of the top securities litigation firms in the United States, consistently ranking in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years. With a team of over 70 legal professionals, Levi & Korsinsky has the expertise and resources to fight for shareholders’ rights.
The Broader Implications of This Case
This lawsuit not only seeks justice for affected shareholders but also highlights concerns regarding corporate transparency and ethical financial practices within the pharmaceutical industry. Regulatory compliance and truthful investor disclosures are fundamental to maintaining investor confidence and market stability. Cases like this underscore the need for stringent oversight and accountability.
